Radicle Calm RDH: A Study Assessing the Impact of Health and Wellness Products on Feelings of Anxiety and Related Health Outcomes

NCT07219628 | Completed

• 1 other identifier: RADX_P_2402_RDH
• Study Type: interventional
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

A randomized, double-blind, placebo-controlled direct-to-consumer study assessing the impact of health and wellness products on feelings of anxiety and related health outcomes.

Conditions

Anxiety

Outcome Measures

Primary Outcomes (1)

• Change in feelings of anxiety

  Change in feelings of anxiety: Difference between rates of change over time in feelings of anxiety score as assessed by PROMIS Anxiety 8A (scale 8-40; with higher scores corresponding to more severe anxiety)

  7 weeks

Secondary Outcomes (3)

• Change in feelings of stress

  7 weeks

• Change in sleep

  7 weeks

• Change in mood (emotional distress-depression)

  7 weeks

Other Outcomes (4)

• Minimal clinically important difference (MCID) in feelings of stress

  7 weeks

• Minimal clinically important difference (MCID) in sleep

  7 weeks

• Minimal clinically important difference (MCID) in mood (emotional distress-depression)

  7 weeks

Study Arms (2)

Placebo Control

PLACEBO COMPARATOR

Calm Product Placebo Control

Dietary Supplement: Calm Product Placebo Control

Active Product 1

EXPERIMENTAL

Calm Active Product 1

Dietary Supplement: Calm Active Product 1

Interventions

Calm Product Placebo Control DIETARY_SUPPLEMENT

Participants will use their Calm Product Placebo Control as directed for a period of 6 weeks.

Placebo Control

Calm Active Product 1 DIETARY_SUPPLEMENT

Participants will use their Calm Active Product 1 as directed for a period of 6 weeks.

Active Product 1

Eligibility Criteria

• Age: 21 Years - 105 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

Participants must meet all the following criteria: * Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities. * Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed. * Resides in the United States. * Has the opportunity for at least 30% improvement in their primary health outcome. * Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study. Individuals who report any of the following during screening will be excluded from participation: * Report being pregnant, trying to become pregnant, or breastfeeding. * Unable to provide a valid US shipping address and mobile phone number * Reports current enrollment in another clinical trial. * Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day). * Unable to read and understand English. * Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk. * Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients. * NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure. * Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients. * Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products. * Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products. * Lack of reliable daily access to the internet.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Radicle Science: lead

Study Sites (1)

Radicle Science Inc.

Del Mar, California, 92014, United States

Location

Related Links

• Related Info

MeSH Terms

Conditions

Anxiety Disorders

Condition Hierarchy (Ancestors)

Mental Disorders

Study Officials

• Susan Hewlings

  Radicle Science

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: The investigator is blinded to the participants' assigned study products. Participants are blinded to the study product they received.
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Participants will be stratified based on their assigned sex at birth and health outcome score during enrollment, then randomized to one of the study arms. Each participant will have an equal chance of being assigned to any study arm.

Study Record Dates

• First Submitted: September 22, 2025
• First Posted: October 22, 2025
• Study Start: September 23, 2025
• Primary Completion: December 14, 2025
• Study Completion: December 14, 2025
• Last Updated: January 14, 2026

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)